161 related articles for article (PubMed ID: 38521468)
1. Recent advances in canonical versus non-canonical Ca
Cauwelier C; de Ridder I; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2024 Jun; 1871(5):119713. PubMed ID: 38521468
[TBL] [Abstract][Full Text] [Related]
2. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
3. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca
Kerkhofs M; La Rovere R; Welkenhuysen K; Janssens A; Vandenberghe P; Madesh M; Parys JB; Bultynck G
Cell Calcium; 2021 Mar; 94():102333. PubMed ID: 33450506
[TBL] [Abstract][Full Text] [Related]
4. The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ signals to mitochondria.
Monaco G; Decrock E; Arbel N; van Vliet AR; La Rovere RM; De Smedt H; Parys JB; Agostinis P; Leybaert L; Shoshan-Barmatz V; Bultynck G
J Biol Chem; 2015 Apr; 290(14):9150-61. PubMed ID: 25681439
[TBL] [Abstract][Full Text] [Related]
5. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
Akl H; La Rovere RM; Janssens A; Vandenberghe P; Parys JB; Bultynck G
Int J Dev Biol; 2015; 59(7-9):391-8. PubMed ID: 26260683
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 Family of Proteins in the Control of Mitochondrial Calcium Signalling: An Old Chap with New Roles.
Morris JL; Gillet G; Prudent J; Popgeorgiev N
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918511
[TBL] [Abstract][Full Text] [Related]
7. Regulation of endoplasmic reticulum Ca2+ dynamics by proapoptotic BCL-2 family members.
Oakes SA; Opferman JT; Pozzan T; Korsmeyer SJ; Scorrano L
Biochem Pharmacol; 2003 Oct; 66(8):1335-40. PubMed ID: 14555206
[TBL] [Abstract][Full Text] [Related]
8. Constitutive IP
Bittremieux M; La Rovere RM; Akl H; Martines C; Welkenhuyzen K; Dubron K; Baes M; Janssens A; Vandenberghe P; Laurenti L; Rietdorf K; Morciano G; Pinton P; Mikoshiba K; Bootman MD; Efremov DG; De Smedt H; Parys JB; Bultynck G
Cell Death Differ; 2019 Mar; 26(3):531-547. PubMed ID: 29899382
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 proteins and calcium signaling: complexity beneath the surface.
Vervliet T; Parys JB; Bultynck G
Oncogene; 2016 Sep; 35(39):5079-92. PubMed ID: 26973249
[TBL] [Abstract][Full Text] [Related]
10. Targeting Bcl-2-IP
Distelhorst CW
Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2-Protein Family as Modulators of IP
Ivanova H; Vervliet T; Monaco G; Terry LE; Rosa N; Baker MR; Parys JB; Serysheva II; Yule DI; Bultynck G
Cold Spring Harb Perspect Biol; 2020 Apr; 12(4):. PubMed ID: 31501195
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Ca
Rosa N; Speelman-Rooms F; Parys JB; Bultynck G
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188791. PubMed ID: 36162541
[TBL] [Abstract][Full Text] [Related]
13. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.
Rong YP; Bultynck G; Aromolaran AS; Zhong F; Parys JB; De Smedt H; Mignery GA; Roderick HL; Bootman MD; Distelhorst CW
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14397-402. PubMed ID: 19706527
[TBL] [Abstract][Full Text] [Related]
14. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
Monaco G; Vervliet T; Akl H; Bultynck G
Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
[TBL] [Abstract][Full Text] [Related]
15. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.
Akl H; Monaco G; La Rovere R; Welkenhuyzen K; Kiviluoto S; Vervliet T; Molgó J; Distelhorst CW; Missiaen L; Mikoshiba K; Parys JB; De Smedt H; Bultynck G
Cell Death Dis; 2013 May; 4(5):e632. PubMed ID: 23681227
[TBL] [Abstract][Full Text] [Related]
16. Altered Ca(2+) signaling in cancer cells: proto-oncogenes and tumor suppressors targeting IP3 receptors.
Akl H; Bultynck G
Biochim Biophys Acta; 2013 Apr; 1835(2):180-93. PubMed ID: 23232185
[TBL] [Abstract][Full Text] [Related]
17. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Ca
Vervliet T; Clerix E; Seitaj B; Ivanova H; Monaco G; Bultynck G
Front Oncol; 2017; 7():75. PubMed ID: 28516063
[TBL] [Abstract][Full Text] [Related]
19. Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival.
Braun F; de Carné Trécesson S; Bertin-Ciftci J; Juin P
Cell Cycle; 2013 Sep; 12(18):2937-47. PubMed ID: 23974114
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling.
Vervloessem T; Kerkhofs M; La Rovere RM; Sneyers F; Parys JB; Bultynck G
Cell Calcium; 2018 Mar; 70():102-116. PubMed ID: 28705421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
